A Biomimetic Autophagosomes-Based Nanovaccine Boosts Anticancer Immunity

Area of Science:

• Immunology
• Nanotechnology
• Biomedical Engineering

Background:

• Personalized cancer vaccines using tumor cell lysates show limited efficacy due to weak tumor antigen immunogenicity.
• Autophagosomes from cancer patients are rich in immunogenic tumor neoantigens but face challenges in lymphatic targeting and antigen-presenting cell uptake.
• Current strategies for cancer immunotherapy require improved vaccine delivery and immune response stimulation.

Purpose of the Study:

• To develop a reinforced biomimetic autophagosome-based (BAPs) nanovaccine for potent antitumor immunity.
• To enhance lymphatic targeting and antigen-presenting cell endocytosis for improved vaccine performance.
• To evaluate the therapeutic efficacy and protective potential of BAPs in preclinical cancer models.

Main Methods:

• Generation of BAPs by combining autophagosome-derived neoantigens with lymph node-targeting adjuvants.
• Utilizing redox-responsive BAPs for controlled cytosolic release of antigens and adjuvants within antigen-presenting cells.
• Assessing BAPs' ability to evoke T-cell responses, eradicate tumors, and confer protection against tumor rechallenge.
• Investigating the synergistic effects of BAPs with checkpoint blockade therapy.

Main Results:

• BAPs effectively eradicated 71.4% of established tumors by evoking broad-spectrum T-cell responses.
• BAPs vaccination led to 100% protection against tumor rechallenge and an 87.5% reduction in tumor incidence, indicating durable immune memory.
• BAPs demonstrated synergistic effects with checkpoint blockade therapy in inhibiting tumor growth in a poorly immunogenic breast cancer model.

Conclusions:

• The developed BAPs nanovaccine represents a potent and versatile platform for personalized cancer immunotherapy.
• This biomimetic approach overcomes limitations of traditional cancer vaccines by enhancing immunogenicity and delivery.
• BAPs show significant promise for eliciting robust and long-lasting antitumor immunity, offering a new strategy for cancer treatment.